Breaking News Instant updates and real-time market news.

LLY

Eli Lilly

$86.79

-0.8599 (-0.98%)

13:10
10/06/17
10/06
13:10
10/06/17
13:10

Eli Lilly announces data from MONARCH 3 study of Verzenio

Eli Lilly and Company announced that interim results from the double-blind, placebo-controlled Phase 3 MONARCH 3 study evaluating Verzenio, a cyclin-dependent kinase 4 & 6 inhibitor, in combination with a nonsteroidal aromatase inhibitor were published online in the Journal of Clinical Oncology. These data, presented at the European Society for Medical Oncology 2017 Congress in September, demonstrated that abemaciclib plus an NSAI resulted in a statistically significant improvement in progression-free survival and objective response rate compared to an NSAI alone in women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. MONARCH 3 met a rigorous threshold for demonstrating efficacy at the time of pre-planned interim analysis with a 46% reduction in the risk of progression or death in patients receiving initial therapy for metastatic disease. The median PFS for abemaciclib in combination with an NSAI was not reached, compared to 14.7 months in the placebo arm. These results are supported by an improvement in response rate, with a 59.2% ORR in patients with measurable disease, including five patients achieving a complete response. Median duration of response was not reached in the abemaciclib-plus-NSAI arm. Final PFS results are expected at the end of the year and will be presented at a scientific congress in 1H18. In MONARCH 3, abemaciclib in combination with an NSAI was generally well tolerated. The most frequent adverse events of any grade in the abemaciclib-plus-NSAI arm were diarrhea, neutropenia, fatigue, infections, and nausea. Of these, the reported Grade 3/4 AEs in the abemaciclib-plus-NSAI arm versus the placebo-plus-NSAI arm were diarrhea, neutropenia, fatigue, infections, and nausea. Severity and frequency of diarrhea generally decreased following 28 days, and was managed with over-the-counter antidiarrheal medication and dose adjustment. The majority of patients in the abemaciclib-plus-NSAI arm with an AE of diarrhea did not require treatment modification and 2.3% of patients discontinued treatment with abemaciclib due to diarrhea

  • 18

    Oct

  • 24

    Oct

  • 06

    Nov

LLY Eli Lilly
$86.79

-0.8599 (-0.98%)

09/18/17
LEER
09/18/17
NO CHANGE
Target $107
LEER
Outperform
Clovis rumors 'unsubstantiated,' but company could be M&A target, says Leerink
Leerink analyst Michael Schmidt noted Bloomberg highlighted speculation claiming that Eli Lilly (LLY) had submitted a $110 per share offer to acquire Clovis (CLVS). While he views the speculation as "unsubstantiated" and the social media sources attributed as "highly questionable," he does think Clovis could be a possible takeout candidate and he does believe the addition of a PARP inhibitor makes a lot of strategic sense for Lilly. He reiterates an Outperform rating and $107 price target on Clovis shares, which are up 9% to $75.91 in afternoon trading.
09/29/17
MSCO
09/29/17
NO CHANGE
Target $86
MSCO
Equal Weight
Morgan Stanley calls Verzenio liver toxicity warning a 'minor' negative surprise
Morgan Stanley analyst David Risinger said he was expecting warnings on diarrhea and blood clot risks for Eli Lilly's (LLY) Verzenio, but not liver toxicity, calling that part of the approval a "minor" negative surprise. However, the approval came ahead of the Q1 timeline management had provided, he added. Bloomberg reports that Verzenio will cost $10,948 per month, which is in-line with the current monthly costs for Pfizer's (PFE) Ibrance and Novartis' (NVS) Kisqali, Risinger noted. He keeps an Equal Weight rating and $86 price target on Eli Lilly shares.
10/05/17
GSCO
10/05/17
NO CHANGE
Target $95
GSCO
Buy
Eli Lilly price target raised to $95 after Alimta patent upheld at Goldman Sachs
Goldman Sachs analyst Jami Rubin noted that the USPTO upheld the validity of all 22 claims on Eli Lilly's method of use patent for Alimta, which he believes restores confidence in the lung cancer drug's durability through its patent expiry in May 2022. Rubin raise his price target on Eli Lilly shares to $95 from $92 and keeps a Buy rating on the stock.
10/06/17
MSCO
10/06/17
NO CHANGE
Target $86
MSCO
Equal Weight
Eli Lilly Alimta patent decision was already assumed, says Morgan Stanley
Morgan Stanley analyst David Risinger said the USPTO final decision upholding Alimta's '209 patent removes an overhang for Eli Lilly, but he also contends that the consensus view was assuming the patent would be upheld. He maintains his Alimta sales estimates and keeps an Equal Weight rating and $86 price target on Eli Lilly shares.

TODAY'S FREE FLY STORIES

LEXEB

Liberty Expedia Holdings

09:50
02/22/18
02/22
09:50
02/22/18
09:50
Hot Stocks
Breaking Hot Stocks news story on Liberty Expedia Holdings  »

Liberty Expedia Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WEN

Wendy's

$16.22

0.12 (0.75%)

09:47
02/22/18
02/22
09:47
02/22/18
09:47
Hot Stocks
Wendy's says testing expanded value menu »

Says raised menu prices…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 07

    Mar

  • 30

    May

TMUS

T-Mobile

$59.42

-1.09 (-1.80%)

, DTEGY

Deutsche Telekom

$16.20

-0.07 (-0.43%)

09:47
02/22/18
02/22
09:47
02/22/18
09:47
Hot Stocks
Deutsche Telekom buys 230K shares of T-Mobile common stock »

In a regulatory filing,…

TMUS

T-Mobile

$59.42

-1.09 (-1.80%)

DTEGY

Deutsche Telekom

$16.20

-0.07 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 26

    Feb

  • 26

    Feb

  • 05

    Mar

LEXEB

Liberty Expedia Holdings

09:45
02/22/18
02/22
09:45
02/22/18
09:45
Hot Stocks
Breaking Hot Stocks news story on Liberty Expedia Holdings  »

Liberty Expedia Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OC

Owens Corning

09:45
02/22/18
02/22
09:45
02/22/18
09:45
Recommendations
Owens Corning analyst commentary  »

Owens Corning price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:45
02/22/18
02/22
09:45
02/22/18
09:45
General news
U.S. leading indicators preview: »

U.S. leading indicators…

09:45
02/22/18
02/22
09:45
02/22/18
09:45
General news
Breaking General news story  »

New York Federal Reserve…

09:45
02/22/18
02/22
09:45
02/22/18
09:45
General news
Leading Indicators to be reported at 10:00 »

January Leading…

SNAP

Snap

09:43
02/22/18
02/22
09:43
02/22/18
09:43
Hot Stocks
Snap slips after Kylie Jenner critique »

Early weakness in shares…Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 07

    Mar

STMP

Stamps.com

$184.95

-5.1 (-2.68%)

09:43
02/22/18
02/22
09:43
02/22/18
09:43
Recommendations
Stamps.com analyst commentary  »

Stamps.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 11

    Mar

  • 23

    May

PG

Procter & Gamble

09:42
02/22/18
02/22
09:42
02/22/18
09:42
Hot Stocks
Procter & Gamble: 'Progress will not come in a straight line' »

Says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 07

    Mar

HST

Host Hotels

, AOBC

American Outdoor Brands

$10.06

-0.12 (-1.18%)

09:40
02/22/18
02/22
09:40
02/22/18
09:40
Options
Unusually active option classes on open February 22nd »

Unusual total active…

HST

Host Hotels

AOBC

American Outdoor Brands

$10.06

-0.12 (-1.18%)

NXPI

NXP Semiconductors

$125.60

0.04 (0.03%)

TMUS

T-Mobile

$59.42

-1.09 (-1.80%)

CHK

Chesapeake

P

Pandora

WMT

Walmart

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 01

    Mar

  • 05

    Mar

  • 07

    Mar

  • 18

    Mar

  • 22

    Mar

  • 23

    Mar

  • 27

    Mar

  • 28

    Mar

LMFA

LM Funding

$1.51

0.08 (5.59%)

, LFIN

Longfin

$34.20

-2.03 (-5.60%)

09:38
02/22/18
02/22
09:38
02/22/18
09:38
Periodicals
LM Funding takeover rumors discussed in web report »

The "GrooveVC"…

LMFA

LM Funding

$1.51

0.08 (5.59%)

LFIN

Longfin

$34.20

-2.03 (-5.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTS

QTS Realty Trust

09:37
02/22/18
02/22
09:37
02/22/18
09:37
Recommendations
QTS Realty Trust analyst commentary  »

QTS Realty Trust price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 04

    Mar

  • 05

    Mar

  • 15

    Mar

  • 03

    Apr

FSLR

First Solar

09:36
02/22/18
02/22
09:36
02/22/18
09:36
Downgrade
First Solar rating change  »

First Solar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 15

    Mar

AVGO

Broadcom

$248.62

-1 (-0.40%)

, QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

09:36
02/22/18
02/22
09:36
02/22/18
09:36
Recommendations
Broadcom, Qualcomm, Xilinx, Analog Devices, Maxim Integrated, Marvell, Microsemi analyst commentary  »

RBC finds takeover…

AVGO

Broadcom

$248.62

-1 (-0.40%)

QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

XLNX

Xilinx

$68.46

-0.73 (-1.06%)

ADI

Analog Devices

MXIM

Maxim Integrated

$61.75

-0.37 (-0.60%)

MRVL

Marvell

$23.19

-0.01 (-0.04%)

MSCC

Microsemi

$60.94

-0.52 (-0.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 06

    Mar

  • 08

    Mar

  • 22

    Mar

IDGX

AltheaDx

09:35
02/22/18
02/22
09:35
02/22/18
09:35
Initiation
AltheaDx initiated  »

AltheaDx initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFM

Sprouts Farmers Market

$26.12

0.12 (0.46%)

09:34
02/22/18
02/22
09:34
02/22/18
09:34
Earnings
Sprouts Farmers Market sees FY18 EPS $1.22-$1.28, consensus $1.23 »

Sees FY18 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SFM

Sprouts Farmers Market

$26.12

0.12 (0.46%)

09:33
02/22/18
02/22
09:33
02/22/18
09:33
Earnings
Sprouts Farmers Market reports Q4 EPS 29c, consensus 15c »

Reports Q4 revenue $1.1B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

NNBR

NN, Inc.

$25.40

0.25 (0.99%)

09:32
02/22/18
02/22
09:32
02/22/18
09:32
Hot Stocks
NN, Inc. acquires Bridgemedica, terms not disclosed »

NN announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

SHPG

Shire

$125.03

-1.64 (-1.29%)

09:31
02/22/18
02/22
09:31
02/22/18
09:31
Recommendations
Shire analyst commentary  »

Shire post results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 23

    Mar

  • 25

    Mar

09:30
02/22/18
02/22
09:30
02/22/18
09:30
General news
U.S. equities are mildly firmer »

U.S. equities are mildly…

AYX

Alteryx

09:30
02/22/18
02/22
09:30
02/22/18
09:30
Recommendations
Alteryx analyst commentary  »

Alteryx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:30
02/22/18
02/22
09:30
02/22/18
09:30
General news
Breaking General news story  »

Week of 2/18 Bloomberg…

WEX

Wex

09:28
02/22/18
02/22
09:28
02/22/18
09:28
Recommendations
Wex analyst commentary  »

Wex price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.